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ABSTRACT Vaginal HIV microbicides offer great promise in preventing HIV transmission, but failures of phase 3 clinical trials,
in which microbicide-treated subjects had an increased risk of HIV transmission, raised concerns about endpoints used to evalu-
ate microbicide safety. A possible explanation for the increased transmission risk is that the agents shifted the vaginal bacterial
community, resulting in loss of natural protection and enhanced HIV transmission susceptibility. We characterized vaginal mi-
crobiota, using pyrosequencing of bar-coded 16S rRNA gene fragments, in samples from 35 healthy, sexually abstinent female
volunteer subjects (ages 18 to 50 years) with regular menses in a repeat phase 1 study of twice-daily application over 13.5 days of
1 of 3 gel products: a hydroxyethylcellulose (HEC)-based “universal” placebo (10 subjects), 6% cellulose sulfate (CS; 13 subjects),
and 4% nonoxynol-9 (N-9; 12 subjects). We used mixed effects models inferred using Bayesian Markov chain Monte Carlo meth-
ods, which showed that treatment with active agents shifted the microbiota toward a community type lacking significant num-
bers of Lactobacillus spp. and dominated by strict anaerobes. This state of the vaginal microbiota was associated with a low or
intermediate Nugent score and was not identical to bacterial vaginosis, an HIV transmission risk factor. The placebo arm con-
tained a higher proportion of communities dominated by Lactobacillus spp., particularly L. crispatus, throughout treatment.
The data suggest that molecular evaluation of microbicide effects on vaginal microbiota may be a critical endpoint that should
be incorporated in early clinical assessment of microbicide candidates.
IMPORTANCE Despite large prevention efforts, HIV transmission and acquisition rates remain unacceptably high. In developing
countries, transmission mainly occurs through heterosexual intercourse, where women are significantly more vulnerable to in-
fection than men. Vaginal microbicides are considered to be one of the most promising female-controlled products, in that
women themselves insert the microbicides into the vagina to prevent HIV transmission during sexual intercourse. The failure of
several microbicides in clinical trials has raised questions concerning the low in vivo efficacy of such anti-HIV molecules. This
study was designed to gain insights into the failures of two microbicides by testing the hypothesis that the microbicides nega-
tively affect a critical line of defense against HIV, the vaginal microbiota. The results suggest that in the early assessment of can-
didate microbicides, culture-independent evaluation of their effect on the vaginal microbiota should be considered and may
constitute a critical endpoint.
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Despite the increasing availability of HIV testing and treat-ment, and campaigns to encourage the adoption of practices
decreasing the risk of HIV transmission, HIV transmission rates
remain unacceptably high (1). HIV poses a particular problem for
many countries in sub-Saharan Africa, where there are about 1.8
million new infections estimated per year, of which 90% or more
are believed to occur through heterosexual intercourse (1). Many
sociocultural and economic factors limit the ability of women to
insist on safer sexual practices to decrease HIV transmission risks.
The development of vaginal HIV microbicides, the use of which
would be controlled or initiated by women, has therefore attracted
much interest as a strategy to help prevent HIV sexual transmis-
sion. A recent clinical trial (CAPRISA004) confirmed that a vagi-
nal topical microbicide containing the antiretroviral agent teno-
fovir applied before and after sex can provide protection against
HIV heterosexual transmission (2). The level of protection ob-
served (54% in highly adherent subjects), however, was less than
might have been expected given the results of preclinical studies
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(3). Even more recently, a different clinical trial (VOICE) of the
same tenofovir gel but with daily application was ended prema-
turely by the Data Safety Monitoring Board because of a lack of
evidence of a beneficial effect (i.e., futility).
Among the first vaginal microbicide agents studied were
nonoxynol-9 (N-9), a nonionic surfactant still widely used as an
FDA-approved spermicide, and cellulose sulfate (CS), a high-
molecular-weight sulfated carboxymethylcellulose polymer.
While initial in vitro and early-phase clinical studies of these mi-
crobicides were promising, the results of larger phase 2B and 3
trials showed no protection against HIV compared to placebo
treatment and an increased risk of infection when the microbi-
cides were used very frequently (4–6). The reasons for the failure
of these agents remain unknown. One hypothesis that may ac-
count for the failure of the microbicides holds that microbicide
application alters the vaginal microbiota so as to yield a vaginal
environment that has lost its natural protective abilities, either
directly enhancing HIV transmission or indirectly acting to acti-
vate potential host cells, which would facilitate HIV transmission.
This hypothesis was further supported by recent work using an in
vitro vaginal microbiota colonization model system (7).
RESULTS AND DISCUSSION
Initial studies found that the microbicides CS and N-9 had limited
effects on conventionally cultured organisms (8, 9) (mainly Lac-
tobacillus sp.), which was not surprising, since cultivation-
dependent methods provide biased quantitative and incomplete
qualitative information on the composition of bacterial commu-
nities (10, 11). In this study, we undertook a comprehensive anal-
ysis of the effects of CS and N-9 on the vaginal microbiota in a
repeat phase 1 study of those agents, using culture-independent
molecular methods and Bayesian statistical modeling. Vaginal
swabs were collected according to the study design outlined in
Fig. 1A. To comprehensively evaluate the effects of the microbi-
cides on the vaginal microbiota, we characterized the vaginal mi-
crobial community taxon composition and relative abundance
using pyrosequencing of bar-coded 16S rRNA gene fragments
(12). A total of 146 longitudinal samples from 35 subjects were
successfully collected and analyzed (Table 1). The microbicides
N-9 and CS, and to some extend the hydroxyethylcellulose (HEC)
placebo, are major inhibitors of PCR amplification. Using the
modified whole genomic DNA extraction procedure developed
for this study, we generated DNA from which variable regions 1
and 2 (V1 and V2) of 16S rRNA genes were successfully amplified.
Pyrosequencing of these bar-coded 16S rRNA gene amplicons
produced a data set consisting of 791,295 high-quality sequence
reads with an average length of 359 bp and 5,420 reads per sample.
Overall, a total of 296 taxa were observed in the vaginal microbiota
of these women. The depth of coverage for each community was
sufficient to detect taxa that constituted ~0.1% of the community.
Complete linkage hierarchical clustering methods were applied
and revealed five major bacterial community state types (CSTs)
(Fig. 1B). Three CSTs were often dominated by different Lactoba-
cillus species: L. crispatus (CST I), L. iners (CST III), or L. gasseri
(CST II) (Fig. 1B; see also Table S1 in the supplemental material).
CST IV-A and CST IV-B were heterogeneous in composition,
without significant numbers of Lactobacillus spp., but differed
from each other in composition. The frequencies of each CST in
this cohort were similar to those previously published (12, 13),
except that CST V was not observed in the subjects enrolled in this
study (Table 1), as its frequency in the general population is less
than 2% (12). Vaginal bacterial communities from samples that
clustered in CST IV-B were characterized by higher proportions
and types of anaerobic bacteria (Fig. 1B; see also Table S1 in the
supplemental material) such as Atopobium, Prevotella, Megas-
pherae, Sneathia, and Mobiluncus, as well as Gardnerella (the latter
in proportions ranging from 0.2% to 9.9%), while CST IV-A com-
prises members of the genera Streptococcus, Enterococcus, and
Escherichia, as well as small proportions of Lactobacillus spp.
(Fig. 1B; see also Table S1 in the supplemental material). CST IV-B
microbial composition is consistent with vaginal communities
found in women with bacterial vaginosis (14, 15) and was associ-
ated with higher Nugent scores, while CST IV-A was associated
with low and intermediate Nugent scores, as shown by modeling
this interaction using a log-linear model (Fig. 2A). Further, using
a mixed effect logistic regression model in which the presence or
absence of G. vaginalis was the outcome variable and CST was the
predictor variable, the log odds ratio of the presence of G. vaginalis
in CST IV-B was shown to be significantly (P  0.001) higher than
in CST IV-A. Other CSTs did not show log odds ratios of the
presence of G. vaginalis significantly different from those seen
with CST IV-A. This holds true if the abundance of G. vaginalis
(ranging from 0.2% to 9.9%) was modeled similarly (p  1e16),
supporting the correlation observed between high Nugent score
and CST IV-B (16). Because high Nugent scores and bacterial
vaginosis have been associated with increased transmission and
acquisition of HIV (17, 18), we evaluated the possibility that CST
IV-B was associated with the application of N-9 or CS. However,
the analysis revealed that 30.8% of the samples were assigned to
CST IV-A (Table 2) and that CST IV-A, not CST IV-B, showed a
statistically significant association with N-9 and CS use at visit V4,
during the middle of the product application period, compared to
placebo and visits V2 and V3 (baseline) (Fig. 2B and 3A). This
result, while surprising, was supported by an analysis of the fre-
quencies of Nugent score categories and product applications over
the study period that showed no differences between the N-9, CS,
or placebo arms (Fig. 3B). Application of the placebo, HEC, does
not appear to affect the frequency of community state types, as
shown by a consistent CST frequency distribution at each visit
before (V3) and during (V4) the application period and immedi-
ately after placebo use ceased (V5) (Fig. 3A). Interestingly, a shift
was observed between visits V5 and V6, when an increase in the
proportion of CST IV-A was observed (Fig. 3A). However, that
shift was not significantly associated with use of the placebo but
certainly represented the normal temporal dynamics of the vagi-
nal microbiota, often observed with the L. iners-dominated CST-
III (13).
To better characterize the effect of N-9 and CS on shifting the
vaginal microbial communities toward CST IV-A, we evaluated
the ability of the communities to not shift to CST IV-A by mod-
eling the distances of each community state from the center of
CST IV-A (see Fig. S1 in the supplemental material). The model
took into account that a subsequent serial microbial community
sample in a particular subject depends on the previous microbial
community (13) and was designed using mixed effects models
inferred using Bayesian Markov chain Monte Carlo methods (see
Materials and Methods). Figure 4 shows the interaction plot of the
mean values and error bars of each sample’s community state with
respect to the distance from the center of CST IV-A for each treat-
ment arm and visit, computed using the mixed effects model.
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Community state distances to the center of CST IV-A for the N-9
and CS groups were significantly different from those for the pla-
cebo group at visit V4 and showed borderline significance at visit
5 (Fig. 4). This analysis highlights the effect of twice-daily appli-
cations of N-9 or CS microbicides on the composition of vaginal
bacterial communities after 7 days of use. Upon application of N-9
or CS, most communities shifted in composition from commu-
nity states that were dominated by species of Lactobacillus to com-
FIG 1 (A) Schematic of the clinical study design. Twice-daily application of the gel products is indicated in green. Idealized menses are indicated in red. Vaginal
swabs were collected at visits 2, 3, 4, 5, and 6. (B) Heatmap of phylotype relative abundances from 146 samples. Ward-linkage hierarchical clustering was
performed on the Jensen-Shannon divergences between all pairs of community states to obtain five community state types. Nugent score categories (high, 7 to
10; intermediate [Int], 4 to 6; low, 0 to 3), treatment arms, and visits are indicated. The top 25 most abundant phylotypes are shown. The frequency of each
community state type is shown in Table 2.
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munity states mainly dominated by anaerobes and by members of
the genera Streptococcus, Enterococcus, and Escherichia (Fig. 1B).
Interestingly, it appears that the vaginal bacterial communities
have the ability to rebound rapidly, as no statistically significant
difference was observed between placebo and N-9 or CS use at
visit 6, 3 days after the last use of the products (Fig. 4). Because
CST IV-A contains low number of Lactobacillus spp., it is antici-
pated that, while not necessarily characterized by high Nugent
scores, this state, like CST IV-B, would contribute to an increased
risk of transmission or acquisition of sexually transmitted infec-
tions (STIs), including HIV. Our results are consistent with pre-
vious culture-based evaluations of N-9 (8, 9), which found that
daily application of N-9 promoted the loss of non-H2O2-
producing lactobacilli and did not affect vaginal colonization by
H2O2-producing lactobacilli (8); however, that earlier study did
not evaluate the effect on other bacteria present in the vagina. The
earlier study also found that N-9 application did not produce in-
creases in the Nugent score. A previous phase I safety study of CS
did not show increases in Nugent scores either; however, it did
show a concomitant reduction in levels of H2O2-producing lacto-
bacilli and an increase in Escherichia coli numbers (19). Further-
more, in that study CS significantly reduced Lactobacillus sp. col-
onization of human cervicovaginal epithelial cells and tissues and
increased their proinflammatory reaction to bacteria (7). Other
polyanions similar to CS have been shown to interfere with Toll-
like receptor (TLR)-mediated responses in human cervicovaginal
cells (20). Effects of the candidate microbicides on vaginal cell
signaling pathways may contribute to observed changes in CSTs
that accompanied application of the microbicide candidates in
our study.
If the N-9 and CS microbicide agents are associated with both
an increased risk of HIV transmission and an alteration in the
vaginal microbiota, it may be helpful to consider what may link
these two phenomena. One potential plausible explanation is that
a distortion in the microbiota may, for example, through interac-
tions with pattern recognition receptors, lead to an increase in
levels of inflammatory cytokines, which would activate potential
HIV host cells. Activation of TLRs in human vaginal cells by mi-
crobial antigens induces innate and proinflammatory responses
(21, 22). Since HIV replicates preferentially in activated cells and
since the risk for HIV transmission at each episode of intercourse
TABLE 1 Number of samples collected per subject included in this study and per treatment arm
Treatment No. of samples per subject No. of subjects Total no. of samples Total no. of samples/treatment Total no. of subjects/treatment
















FIG 2 (A) Interaction plot of the mean values and error bars of the log counts
of the community state types versus Nugent score category contingency table
(see Table S4 in the supplemental material) stratified by community state type
and Nugent category, with error bars indicating 95% credible intervals derived
from model 2 (described in Materials and Methods). (B) Interaction plot of the
mean log(odds) values and the corresponding 95% credible interval of logistic
regression model 1, evaluating the association between CSTs (community
state types) at visit V4 compared to visits V2 and V3 for each product use arm.
In the N-9 (V4) and CS (cellulose sulfate) (V4 and V5) arms, no communities
were assigned to CST II. In addition, in the N-9 arm (V4), no communities
were assigned to CST III (Fig. 4).
Ravel et al.
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is low, increasing potential host cell activation may reasonably be
expected to affect overall transmission rates.
The present study, despite the relatively small number of sub-
jects, demonstrated using culture-independent methods that ap-
plication of microbicides associated with higher rates of HIV
transmission can affect the composition of the vaginal microbiota,
although it is impossible to say whether these changes are specific
to the active agent or to one or more other components of the
microbicide vehicle gel, given that the universal placebo has a
composition different from those of the vehicles of both N-9 and
CS gels. These changes in the vaginal microbiota could plausibly
contribute to higher rates of HIV transmission. While our obser-
vation involves candidate microbicides that have been shown to
be ineffective at preventing HIV transmission in large phase 3
clinical trials, an analogous effect could produce a decrease in the
effectiveness of microbicides that do help prevent HIV transmis-
sion. The data suggest that molecular, culture-independent eval-
uation of microbicide effects on vaginal microbiota, in addition to
or combined with culture-based methods, may be an important
component of the early clinical assessment of candidate microbi-
cides. The data also suggest that the development of a maximally
effective HIV microbicide delivery system may require, in addi-
tion to agents focused solely on the virus, components that help
maintain or promote a healthy vaginal microbial community.
MATERIALS AND METHODS
Clinical sampling and study design. The samples were obtained in the
course of a carefully monitored repeat phase 1 study of CS and N-9,
conducted by CONRAD (protocol no. A04-097). Sixty healthy, sexually
abstinent female (tested using Rapid Stain Identification Series [RSID]-
Semen) volunteer subjects (ages 18 to 50 years) with regular menstrual
cycles (27 to 35 days) not using systemic hormonal contraception, sys-
temic corticosteroid antibiotics, antifungals, or antivirals and without
vaginal candidiasis, bacterial vaginosis, sexually transmitted infections, or
urinary tract infections were recruited for the study and randomly as-
signed to use one of the following three gel products in a blinded fashion:
a hydroxyethylcellulose (HEC)-based “universal” placebo (96% purified
water [USP], 2.7% hydroxyethyl cellulose [NF], 0.85% sodium chloride
[NF], 0.1% sorbic acid [NF], sodium hydroxide [NF] to pH 4.4); 6%
cellulose sulfate in a gel vehicle that included humectants glycerin and
sorbitol, a thickener (carbomer), water, and benzyl alcohol as a preserva-
tive; or 4% nonoxynol-9 (Conceptrol) gel, which includes lactic acid,
methyl paraben, povidone, propylene glycol, purified water, sodium car-
boxymethyl cellulose, sorbic acid, and sorbitol. The subjects were in-
structed to insert their assigned gel twice daily into the vagina for 13.5 days
(27 applications of about 3.5 ml each). Tests for seminal fluid were con-
ducted at each visit to confirm that subjects remained abstinent during the
course of the study. Vaginal swabs were obtained 14 days prior (V2) and
just prior (V3) to the first product application, after the 13th (V4) and last
(27th) (V5) applications, and 3 days after (V6) the end of product use
(Fig. 1A). V1 was the designation for the initial screening visit, and vaginal
swabs were not obtained at that time. At least 8 h separated the insertion of
product and sampling. A physician inserted a speculum lubricated with
sterile saline water and sampled the midvaginal walls using an Elution
Swab system (Copan). The swab was immediately placed into 1 ml of
Amies transport medium, frozen upright, and stored at 80°C. Addi-
tional examinations included naked-eye examinations, colposcopies, cer-
vicovaginal lavages, and vaginal smears for Nugent scores (16). Partici-
pants were queried about adverse events at each visit.
A total of 60 women were enrolled in the parent study; however, be-
cause Institutional Review Board (IRB) approval for this aspect of the
study was not received until after the start of subject enrollment, samples
for vaginal microbiota analysis were not collected from 10 subjects and
only one sample was collected from each of several subjects (4 CS, 3 N-9,
and 4 placebo subjects). Another 11 subjects were dropped from the anal-
ysis (2 CS, 3 N-9, and 4 placebo subjects deviated from the protocol, and
2 subjects dropped out before randomization). In addition, 35 processed
samples were not included in the analysis because the total high-quality
read count was less than 500. A total of 146 samples from 35 subjects (13
CS, 12 N-9, and 10 placebo) were included in the analysis (Table 1). The
study was double blinded.
The study was approved by the institutional review boards at East-
ern Virginia Medical School, Children’s National Medical Center, the
University of Maryland School of Medicine, and the University of
Pittsburgh.
Nugent Gram stain analysis. The vaginal smears were heat fixed and
Gram stained and then blinded and read in random order. A microscopy
score of 0 to 10 was assigned by an experienced microbiologist using the
standardized method described by Nugent et al. (16). Nugent scores re-
flect composite scores based on the cellular morphology of the bacteria
present in a sample. A score of 0 to 3 is designated normal, 4 to 6 inter-
mediate, and 7 to 10 abnormal and indicative of bacterial vaginosis.
Microbial DNA isolation in the presence of microbicides. Because
the nonionic surfactant N-9 and the large polyanion CS were found to
interfere with post-DNA-extraction PCR amplification, cell suspensions
were first washed prior to lysis to remove the water-soluble microbicide.
The use of the flocked nylon swabs facilitated the release of microbial cells
in Amies transport media though gentle swirling of the tube (bacteria do
not strongly adhere to the nylon swab’s axially arrayed fibers and are easily
released without the need of a vortex procedure). A total of 1 ml of cell
suspension in transport medium was pelleted by centrifugation at 10,000
 g for 10 min and washed twice in 2 ml of 5 mM phosphate-buffered
saline (PBS), with bacteria recovered by centrifugation at 10,000  g for
10 min. After the washes, the cells were resuspended in 2 ml of 5 mM PBS
and the suspension was treated with 250 U of cellulase (Sigma-Aldrich)
overnight at 37°C. The cells were then washed one more time in 2 ml of
5 mM PBS, centrifuged at 10,000  g for 10 min, and resuspended in
250 l of 5 mM PBS. Cell lysis and DNA extraction were performed
according to Ravel et al. (12), using enzymatic and mechanical lysis. This
procedure yielded between 2.5 and 5 g of high-quality, PCR inhibitor-
free whole genomic DNA per vaginal swab. The sequence data are avail-
able in the NCBI Sequence Read Archive (SRA) (SRA058693) under study
accession no. SRP015721.
DNA amplification and pyrosequencing of bar-coded 16S rRNA
genes. PCR amplification and 454 pyrosequencing of the V1-V2 hyper-
variable regions of 16S rRNA genes were performed as previously de-
scribed (12) using primers 27F and 338R (23).
Sequence analysis. The QIIME software package was used for quality
control of sequence reads using the following criteria. Sequences were
required to (i) have minimum and maximum lengths of 220 bp and
400 bp; (ii) have an average quality score of q25 over a sliding window of
50 bp (if quality dropped below q25, the read was trimmed at the first base
pair of the window and then reassessed for length); (iii) have a perfect
match to a bar code sequence; and (iv) include the presence of the 16S
primer used for amplification (338r). Sequences were binned by samples
using the sample-specific bar code sequences and trimmed by removal of
TABLE 2 Metadata and taxonomic composition of each sample
analyzed






a As defined by Ravel et al. (12).
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the bar code and primer sequences (forward [if present] and reverse).
High-quality sequence reads were first dereplicated using 99% similarity
and the UCLUST software package, and detection of potential chimeric
sequences was performed using the UCHIME component. Chimeric se-
quences were removed prior to taxonomic assignments. Each processed
16S rRNA gene sequence was classified using the RDP naive Bayesian
Classifier (24). RDP classifier quality score filtering was not used, and all
reads were classified to the genus or species level as described previously
(12). All sequence reads taxonomically assigned to the genus Lactobacillus
were identified to the species level using the SpeciateIT software package
FIG 3 (A) Nugent score category proportions for each treatment and visit. (B) Nugent score categories (high, 7 to 10; intermediate, 4 to 6; low, 0 to 3). There
is no significant difference between the values from the baseline and visits V4, V5, and V6.
Ravel et al.
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(http://speciateIT.sourceforge.net). Taxonomic assignments are shown in
Table S1 in the supplemental material.
Jensen-Shannon divergence. Jensen-Shannon divergence is a mea-
sure of dissimilarity between probability distributions that was intro-
duced by Lin (25) to alleviate the limitations associated with relative en-
tropy (13). The Jensen-Shannon divergence between the two discrete
probability distributions p  (p1, . . ., pn) and q  (q1, . . ., qn) is defined as
follows:
DJSp, q
DKLp, a DKLq, a
2
where a  (p  q)/2 is the average of p and q, and DKL(x,y) is the relative
entropy between x and y. The values of the Jensen-Shannon divergence
are normalized to lie between 0 and 1, and its square root is a metric that
we refer to as the Jensen-Shannon metric.
The Jensen-Shannon divergence can be expressed using entropy with
the following formula:
DJSp, q Hp  q2  H
p Hq
2
Statistical analyses. Using the methods described previously by Ravel
et al. (12), each sample of a vaginal bacterial community, which represents
a state of the community at a given time point (community state), was
assigned to one of five CSTs (groups of community states with similar
microbial species compositions and abundances) using complete linkage
hierarchical clustering methods (Fig. 1B).
Modeling the association between CST frequency and product use
at V4. CST IV-B, characterized by a lack of Lactobacillus spp. as well as the
presence of a variety of strict anaerobes, is often associated with high
Nugent scores (14, 16). Because high Nugent scores and bacterial vagino-
sis have been associated with increased risks of transmission and acquisi-
tion of several STIs (17, 26–28), including HIV (17, 18), we tested for an
association between the frequency of each community state type and
product use at visits V2 and V3 and at visit V4. More precisely, the follow-
ing mixed effects logistic regression model was fitted to the data:
yi  Bernoullipi,
logitpi a  btrmti cstTypei dtrmti,stTypei esubjIdi,
es  Norm0, b
where Bernoulli(p) is the Bernoulli distribution with mean p, y ~ Bernoulli(p)
means that y is sampled from the distribution Bernoulli(p), and yi is the
indicator variable. It is set equal to 0 if the “i”th sample was collected at
visits V2 and V3 and set equal to 1 if it was collected at visit V4. trmt(i),
stType(i), and subjId(i) are the treatment arm, community state type, and
subject identification number (id), respectively, of the community state
corresponding to the “i”th sample. The reference class for the treatment
variable is the placebo group. The reference class of the community state
type variable is CST IV-A. Thus, the baseline group for the model de-
scribed above consists of placebo samples at CST IV-A. The coefficient a is
the mean log odds ratio of samples at visit V4 versus visit V2 or V3 for the
baseline group of samples, and b and c are the main effects of treatment
and community state type, respectively. The coefficient d captures the
interaction between treatment and CST. In order to take into account
interactions between samples from the same subject, the model includes a
random intercept term (e) that depends on subject id. Estimation of the
coefficients of the model was done using Just another Gibbs sampler and
jags (29) and the rjags R package (30, 31). A noninformative gamma prior
with the shape parameter 1 and a scale parameter of 1,000 was used for the
precision of the normal distribution, and for the other parameters, the
prior was set to the normal distribution with a mean of 0 and a standard
deviation of 1,000. Convergence of Markov chains in the model described
above was verified using the Gelman-Rubin potential scale reduction fac-
tor test (32) at the 1.1 level and the coda R package (33). All Markov chain
models were run using 100,000 iterations (with a 100,000-iteration burn-
in) and a thinning value of 100. The coefficients and their 95% credible
intervals are presented in Table S2 in the supplemental material. This
analysis revealed that CST IV-B was not associated with product use but
that CST IV-A was associated with both N-9 and CS application. To fully
characterize this association, we evaluated the ability of the community to
not enter CST IV-A by modeling the distances of each community from
the center of CST IV-A (see Fig. S1 in the supplemental material). This was
accomplished using mixed effects models inferred using Bayesian Markov
chain Monte Carlo methods.
Modeling the effect of product application on the community dis-
tance from the center of CST IV-A. In order to measure the effect of
microbicide treatment on community distance from the center of CST
IV-A (see Fig. S1 in the supplemental material), we have used the follow-
ing double exponential mixed effects model. Community distances were
calculated using the Jensen-Shannon divergence:
yi  DExpi, trmti,
i  a  btrmti cvisiti dtrmti,vsiti esubjIdi,
es  Norm0, b
where DExp(, ) is the double exponential distribution with mean 
and standard deviation , y ~ DExp(, ) means that y is sampled from
the distribution DExp(, ), and yi, trmt(i), visit(i), and subjId(i) are the
distances from the center of community state type IV-A, treatment arm,
visit, and subject id, respectively, of the community state corresponding to
the “i”th sample. The distance from the center of the CST IV-A was com-
puted in the Principal Coordinate Analysis (PCoA) three-dimensional
(3D) space, where PCoA was done based on the Jensen-Shannon metric
between community states. The center of the CST IV-A was defined as the
median position in the PCoA 3D space of CST IV-A community states.
The distances to the center of IV-A were computed using the Manhattan
metric. The reference class for the treatment variable is the placebo group.
The reference class of the visit variable consists of visits V2 and V3. Thus,
the baseline group for the above model consists of placebo samples at
visits V2 and V3. In the above-described model, the within-sample vari-
ance depends on the treatment arm. The coefficient a is the mean distance
to CST IV-A for the baseline group of samples, and b and c are the main
effects of treatment and visit, respectively. The coefficient d captures the
interaction between treatment and visit. In order to take into account
interactions between samples from the same subject, the model includes a
random intercept term, e, that depends on subject id. Estimation of the
coefficients of the model was done using Just Another Gibbs Sampler and
jags (29) and the rjags R package (30, 31). A noninformative gamma prior
with the shape parameter 1 and a scale parameter of 1,000 was used for the
precision of the normal distribution, and for the other parameters, the
prior was set to the normal distribution with a mean of 0 and a standard
deviation of 1,000. Convergence of Markov chains in the above-described
FIG 4 An interaction plot of the mean values and error bars of the distance
from the center of CST IV-A for different treatment arms and visits, based on
the mixed effects model (model 1). Error bars indicate 95% credible intervals.
The higher frequency of CST IV-A at visits V4 and V5 for treatments with CS
and N-9 is notable.
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model was verified using the Gelman-Rubin potential scale reduction
factor test (32) at the 1.1 level using the coda R package (33). All Markov
chain models were run using 100,000 iterations (with a 100,000-iteration
burn-in) and a thinning value of 500. The coefficients and their 95%
credible intervals are presented in Table S3 in the supplemental material.
Modeling the association between Nugent score category and com-
munity state type. The structure of the log-linear model for the Nugent
category versus community state type contingency table is as follows:
yi  Poissoni,
logi a  bnugCati cstTypei dnugCati,stTypei
where yi, nugCat(i), and stType(i) are the counts, Nugent score category
(low  0 to 3, intermediate  4 to 6, and high  7 to 10), and community
state type of the “i”th cell of the contingency table (see Table S4 in the
supplemental material). Estimation of the coefficients of the model was
done using Just Another Gibbs Sampler and jags (29) and the rjags R
package (30, 31). A noninformative normal distribution with a mean of 0
and a standard deviation of 1,000 was used for all coefficients of the model.
Convergence of Markov chains in this model was verified using the
Gelman-Rubin potential scale reduction factor test (32) at the 1.1 level
and the coda R package (33). The model was run for 50,000 iterations
(with a 50,000-iteration burn-in) and a thinning value of 100. Coefficients
and their 95% credible intervals for this model are presented in Table S5 in
the supplemental material.
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